DYNABIO S.A. is a biotechnology company established in 1992 to promote the clinical use of newly discovered stress proteins. Research and development was initially focussed on the Pancreatitis-Associated Protein (PAP), the first member of a new class of stress proteins whose expression reflects with extreme sensitivity pathological alterations of several tissues in the gastrointestinal tract.

Close partnership was established between DYNABIO S.A. and INSERM laboratories working on such proteins and the company was granted by INSERM (http://www.inserm.fr/) exclusive licencing of the PAP patents covering the clinical use of PAP antibodies and the use of the PAP assay in cystic fibrosis neonatal screening.

An ELISA for PAP was constructed and several clinical research projects were instigated to evaluate the interest of monitoring PAP in various pathologies. They provided ground for commercial development of the product. The PancrePAP kit is presently distributed worldwide and the number of potential applications is growing (see Documentation section).

More recently, demonstration in a large-scale multicenter study that PAP assay, coupled with immunoreactive trypsinogen assay, allowed newborn screening for cystic fibrosis (see Documentation section) led to the development of a new kit adapted to newborn screening, called MucoPAP.

DYNABIO S.A. is developing new immunological tools to improve detection of PAP. Its facilities are located on the Luminy campus in Marseille -France- (http://www.agl.univ-mrs.fr) , in a very dynamic environment with strong academic research in Immunology and a growing number of biotechnology companies.